Althea Group (ASX:AGH) - CEO, Joshua Fegan
CEO, Joshua Fegan
Source: Althea Group/Youtube
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Althea Group (AGH) is getting ready to raise more capital, while also announcing a new deal with a Canopy Growth Corporation subsidiary
  • AGH placed its shares in a trading halt on Monday morning, with full details of the fundraise set to be released by Wednesday, August 25
  • The cannabis business also announced today that its subsidiary, Peak Processing Solutions, has signed a deal with Supreme Cannabis
  • Under the manufacturing agreement, Peak will perform extraction services for Supreme with minimum order quantities of C$600,000 (A$655,000)
  • Shares in Althea Group last traded at 28.5 cents each

Althea Group (AGH) is getting ready to raise more capital, while also announcing a new deal with a Canopy Growth Corporation’s subsidiary.

AGH placed its shares in a trading halt on Monday morning, with full details of the fundraise set to be released by Wednesday, August 25.

The cannabis business also announced today that its subsidiary, Peak Processing Solutions, has signed a deal with Supreme Cannabis.

Supreme is a subsidiary of Canopy Growth, which is one of the world’s largest cannabis companies.

Under the manufacturing agreement, Peak will perform hydrocarbon extraction services to create various concentrate products for Supreme using their cannabis.

The deal has minimum order quantities of C$600,000 (A$655,000) over one-year, with the agreement able to be extended.

Althea Group CEO Joshua Fegan said he was pleased to see Peak sign another deal, with the subsidiary bringing in $1.52 million in revenue over FY21

“It’s pleasing to see Peak sign yet another substantial manufacturing agreement with such a strong and recognised licensed producer in the Canadian recreational cannabis market,” Mr Fegan said.

“This really highlights the capabilities of the Peak business and further exemplifies the confidence that premium brands are placing in the team at Peak.”

AGH expects Peak to generate $15 million in revenue over FY22, with its own pharmaceutical cannabis business achieving revenue of $10.02 million in FY21.

Shares in Althea Group last traded at 28.5 cents each.

AGH by the numbers
More From The Market Herald
The Market Herald Video

" Cynata Therapeutics (ASX:CYP) to conclude MEND trial following strategic review

Cynata Therapeutics (ASX:CYP) has completed a strategic review of its clinical development pipeline to maximise commercial…
The Market Herald Video

" AVITA Medical (ASX:AVH) reports positive results from soft tissue trial

AVITA Medical (ASX:AVH) reports positive top line results for its RECELL trial in patients with soft-tissue…
Paradigm Biopharmaceuticals (ASX:PAR) - CEO, Marco Polizzi

" Paradigm Biopharmaceuticals (ASX:PAR) enters trading halt amid cap raise

Paradigm Biopharmaceuticals (ASX:PAR) has entered into a trading halt ahead of a capital raise.
HITIQ (ASX:HIQ) - CEO, Mike Vegar

" HITIQ (ASX:HIQ) secures third Australian innovation patent

HITIQ (ASX:HIQ) has secured a third Australian innovation patent related to its virtual reality (VR) concussion…